Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

79.0K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
79.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026
Same author

Continuous Apomorphine Infusion in Multiple System Atrophy Real-World Insights From a French Nationwide Retrospective Cohort.

Movement disorders clinical practice·2026
Same author

The LRRK2 G2385R Exonic Variant: A Potential Genetic Disease Modifier of Multiple System Atrophy?

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Dorsal Raphe VIP Neurons Are Critical for Survival-Oriented Vigilance.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Reply to: Deep Learning to Differentiate Parkinsonian Syndromes: From Proof of Concept to Clinical Trust.

Movement disorders : official journal of the Movement Disorder Society·2025

Related Experiment Video

Updated: Aug 1, 2025

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.0K

GRK2-Targeted Knockdown as Therapy for Multiple System Atrophy.

Miguel Lopez-Cuina1,2,3,4, Paul Guérin1,2, Nathalie Dutheil1,2

  • 1Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.

Movement Disorders : Official Journal of the Movement Disorder Society
|April 24, 2023
PubMed
Summary
This summary is machine-generated.

Lowering brain G-protein-coupled receptor kinase 2 (GRK2) levels may reverse insulin resistance in Multiple System Atrophy (MSA). This neuroprotective strategy reduced dopamine neuron loss and alpha-synuclein aggregation in a mouse model.

Keywords:
in uteroinsulin resistancesynucleinopathy

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.7K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.5K

Related Experiment Videos

Last Updated: Aug 1, 2025

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.0K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.7K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.5K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Multiple system atrophy (MSA) is a rare, adult-onset neurodegenerative disease linked to alpha-synuclein aggregation.
  • Central nervous system insulin resistance is implicated in MSA pathogenesis and may represent a therapeutic target.
  • G-protein-coupled receptor kinase 2 (GRK2) is identified as a key inhibitor of insulin signaling in the brain.

Purpose of the Study:

  • To investigate whether reducing brain GRK2 levels can reverse insulin resistance in the context of MSA.
  • To evaluate the neuroprotective potential of targeting GRK2 in a mouse model of MSA.

Main Methods:

  • Utilized viral-mediated delivery of a GRK2-specific microRNA (miRNA) to lower GRK2 abundance in the brain.
  • Employed the transgenic PLP-SYN mouse model, which mimics aspects of MSA.
  • Administered the GRK2 miRNA either prenatally (in utero intracerebroventricularly) or postnatally (intrastriatally) to target developing or established insulin resistance.

Main Results:

  • Viral vector delivery of GRK2 miRNA demonstrated neuroprotective effects in both developing and adult PLP-SYN mice.
  • Reduced striatal GRK2 levels correlated with preserved substantia nigra dopamine neurons.
  • Therapeutic intervention led to decreased high-molecular-weight alpha-synuclein species and ameliorated insulin resistance.

Conclusions:

  • These findings highlight GRK2 as a promising therapeutic target for Multiple System Atrophy.
  • Targeting GRK2 may offer a novel strategy to counteract neurodegeneration and insulin resistance in MSA.